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Abstract 
 
Objectives 
Data quantifying outcomes of recurrent Clostridium difficile infection (rCDI) are lacking. We sought to 
determine the UK hospital resource use and health-related quality of life (HrQoL) associated with rCDI 
hospitalisations. 
Patients and methods 
A non-interventional study in 6 UK acute hospitals collected retrospective clinical and resource use 
data from medical records of 64 adults hospitalised for rCDI and 64 matched inpatient controls with a 
first episode only (f)CDI. Patients were observed from the index event (date rCDI/fCDI confirmed) for 
28-days (or death, if sooner); UK-specific reference costs were applied. HrQoL was assessed 
prospectively in a separate cohort of 30 patients hospitalised with CDI, who completed the EQ-5D-3L 
questionnaire during their illness. 
Results 
The median total management cost (post-index) was £7,539 and £6,294 for rCDI and fCDI, respectively 
(cost difference, p=0.075); median length of stay (LOS) was 21 days and 15.5 days, respectively 
(p=0.269). The median cost difference between matched rCDI and fCDI cases was £689 (IQR=£-1,873-
£3,954). Subgroup analysis demonstrated the highest median costs (£8,542/patient) in severe rCDI 
cases. CDI management costs were driven primarily by hospital LOS, which accounted for >85% of 
costs in both groups. Mean EQ-5D index values were 46% lower in CDI patients compared with UK 
population values (0.42 and 0.78, respectively); EQ-VAS scores were 38% lower (47.82 and 77.3, 
respectively). 
Conclusions 
CDI has considerable impact on patients and healthcare resources. This multicentre study provides a 
contemporaneous estimate of the real-world UK costs associated with rCDI management, which are 
substantial and comparable to fCDI costs. 
  
Introduction 
Clostridium difficile infection (CDI) is a major public health challenge worldwide, and is associated with 
significant morbidity, mortality and healthcare resource utilisation.1–5 In the UK, although CDI reports 
decreased by 61% between 2007/08 and 2010/11 following the introduction of national surveillance, 
there was a 6% increase in CDI cases in England (from 24.8-26.3/100,000 population) between 
2013/14 and 2014/15.6–8  
A recent study undertaken in 2012-13 across 482 hospitals in 20 European countries reported a CDI 
incidence of 7 cases/10,000 patient-bed days, a 70% increase on rates recorded in 2008. Furthermore, 
when diarrhoeal samples were re-tested by an optimised method for diagnosing CDI, about a quarter 
of cases had been missed locally; consequently, the true rate of CDI in Europe is probably much 
higher.9 In the US, C. difficile was recently reported to be the most common cause of healthcare 
associated infection, with approximately half-a-million CDI cases and 29,000 deaths in 2011.10  
It is estimated that recurrent CDI (rCDI) following initial resolution occurs in 20-30% of patients.11–13 
However, data on the burden and outcomes associated with rCDI are scarce. Surveillance systems may 
fail to capture many rCDI cases given that re-testing of patients with symptoms suggestive of rCDI may 
not occur. Notably, mandatory surveillance data in England largely exclude rCDI cases, as the collected 
figures exclude repeat laboratory-positive results within 28-days from the same patient.8 There is a 
lack of contemporaneous information quantifying the economic burden of CDI in the UK, and 
particularly the resource use associated with recurrent episodes. Such costs have growing relevance 
as new therapeutic options become available that reduce rCDI rates compared with conventional 
treatments.14,15  
In addition to the economic burden, it is important to consider the impact of new CDI therapeutics on 
health-related quality of life (HRQoL); this may be impaired in CDI patients due to decreased functional 
capacity and anxiety about physical symptoms or complications.16,17 Despite the high incidence of CDI, 
its impact on HRQoL has not been widely studied and therefore conventional economic analyses may 
underestimate the true burden. 
This industry-initiated study aimed to quantify the cost of hospital resource use (HRU) for patients 
with rCDI and describe the impact of CDI on HRQoL. The study was initiated by Merck Sharp and 
Dohme Limited (MSD) prior to the Phase 3 study for bezlotoxumab, which has subsequently been 
approved for prevention of CDI recurrence and was designed to provide “real-world” data that can be 
used to help determine the cost-effectiveness of new CDI management options.  
 
Methods  
A mixed-methodology non-interventional study was conducted between September-2013 and 
September-2014 in six geographically-dispersed UK National Health Service hospitals. Potential 
hospital sites likely to provide sufficient study participants and representation across NHS England 
regions and Scotland were identified by the lead investigator, study sponsor, and by review of Health 
Protection Agency (now PHE) mandatory surveillance data. Potential hospitals were approached and 
subsequently recruited to the study on the basis of their ability/capacity to deliver the study data 
collection requirements (including database systems that would allow identification of eligible 
patients; availability of local clinical staff to seek informed consent and collect the required data; and 
confirmed participant availability). Financial support for individual centres was provided in line with 
the National Institute for Health Research (NIHR) costing template, as is standard for studies 
implemented in the UK. Ethics committee (London-Brent, reference 13/LO/1046) and relevant local 
approvals were obtained. The study was undertaken in two parts: 
Part 1: Matched retrospective cohort study 
Design 
A matched retrospective cohort study covering an observation period of 01-March-2012 to 02-June-
2014 gathered clinical and HRU data from the medical records of patients hospitalised for rCDI and 
matched patients from the same centres, with a first episode of CDI but no recurrence (fCDI). The 
design and flow is summarised in Figure 1. 
Patients 
rCDI cases were adult (≥18 years) inpatients with a positive CD toxin test after 01-May-2012 (the index 
result) and any previous positive CD toxin test in the ≤12-weeks before this result. Potential patients 
were identified from microbiology records and eligibility confirmed by cross-referencing with hospital 
administration systems and full CDI testing records. Patients were included in the final dataset only 
where a matched (fCDI) control was identified (see below). May-2012 was chosen as the start of the 
observation period because the UK Department of Health issued revised guidance on C. difficile 
diagnosis and reporting in March-2012; hence, it was considered that there would be greater 
uniformity between centres in CDI testing after this date.18 It was expected (although not confirmed) 
that included CDI cases would have been diagnosed according to this guidance; although all patients 
identified as eligible by the participating centres were included. 
Matched fCDI controls were patients with a first CDI episode (community or healthcare-facility 
acquired) but no subsequent positive CD toxin test within the 12-weeks following last CDI treatment, 
who matched a rCDI case according to date of first positive CD toxin test (±12-weeks), age group 
(<75/≥75 years) and gender. 
Patients were excluded if they transferred hospital trusts or died before the end of CDI treatment. All 
eligible paired patients were included. Patient consent was not required since this part of the study 
involved only routinely-collected clinical data gathered in pseudo-anonymised form by members of 
the direct care team. 
Data collection 
Pseudo-anonymised data were collected retrospectively by local clinical staff from eligible patients’ 
hospital medical records using a standard data collection form. The dataset comprised baseline 
demographics; co-morbidities; CDI strain and illness severity at first episode (both groups) and 
recurrence (rCDI only); and HRU (hospital admission and discharge dates, length of stay [LOS] per 
ward/side room, outpatient appointments, Emergency Department [ED] attendances, prescribing, 
diagnostic tests, supplementary nutrition). HRU data were collected for the ‘post-index’ period, 
defined as the period between the index event (date rCDI or fCDI first confirmed by positive CD toxin 
test) and 28-days post-index or death, whichever was shorter. A 28-day observation period was 
chosen to reduce the risk of the results being skewed by non-CDI-related resource. Due to the acute 
nature of the disease, HRU occurring after 28-days was considered much less likely to be attributable 
to CDI. For rCDI, data were also collected for the ‘between-episode’ period (from 72-hours after end 
of treatment for the first CDI episode until the index event).  
Resource costs were calculated using UK-specific reference costs (Supplementary appendix 1) and a 
Market Forces Factor Index applied to the costs for each Trust.19–30 
Outcomes 
The primary outcome was the difference in total hospital management costs between patients with 
rCDI and fCDI. Secondary outcomes included the difference in the number of days hospitalised during 
the post-index period and total management costs for the between-episode period (rCDI only). 
Statistical analysis 
We aimed to include 75 rCDI and 75 fCDI patients in the study. As there are no UK estimates of rCDI 
costs, the sample size was based on US data, which showed an average LOS for rCDI of 9-days and a 
cost range of $3,500-$5,000/recurrence (1999 Dollars).31 Assuming similar UK costs and using the mid-
point of this estimate converted to UK pounds (£2,800), a sample of 75 patients provided a 95% CI of 
£2,623-£2,977 (±£177 [6%]); this was considered to be interpretable to clinicians and payers given the 
magnitude of the cost difference between established and more expensive new therapeutics. Six 
study centres were used, with the expectation of achieving the recommended sample size based on 
expected numbers of eligible paired patients. 
Analysis was conducted using Microsoft Excel on the available data, with no imputation of missing 
values apart from a set of pre-specified assumptions (Supplementary Appendix 1). The number of 
patients available for each analysis is stated where data were missing. Descriptive endpoints are 
presented using the mean (standard deviation, SD), median (IQR) or percentages, as appropriate. The 
difference between rCDI and fCDI patients in the median total cost of treating CDI and the median LOS 
during the post-index period was compared using the Wilcoxon rank-sum test. 
HRU endpoints are presented overall and stratified by CDI severity (a planned subgroup analysis). 
Severe CDI was defined by the presence of any of the following criteria: white cell count >15x109/L, 
acutely rising blood creatinine (e.g. >50% increase above baseline), temperature >38.5oC or evidence 
of severe colitis (abdominal signs, radiology).32 When none of these was present, CDI was classified as 
mild/moderate.  
Part 2: Prospective patient self-assessment of QoL 
Design 
As HRQoL is not routinely measured and documented in medical records, it was assessed prospectively 
in a separate cohort of adult patients from the same centres, who were hospitalised with CDI. Eligible 
patients completed the EQ-5D-3L questionnaire33,34 during their illness, within five-days of symptom 
onset. Questionnaires were completed between 10-September-2013 and 07-August-2014. 
Demographic and disease history data including gender, age and CDI severity were recorded from the 
patients’ medical records.  
Patients 
Patients were included if they had a positive CDI test, were hospital inpatients and aged ≥18 years at 
the date of the positive CDI test and consented to complete the questionnaire. Owing to the lack of 
data on HRQoL in CDI patients in general, part 2 was not restricted to rCDI and all patients with CDI 
(both first and recurrent episodes) were eligible for inclusion. Potentially eligible patients were 
identified from microbiology records and, if considered by clinical staff to be competent to consent, 
they were approached by a member of their care team with study information and asked if they 
wished to participate. Only consenting patients were included. Consecutive eligible patients were 
invited until the recruitment target was met (30 patients, maximum 10 patients/centre). A sample size 
of 30 patients was recommended, based on the Central Limit Theorem, assuming the results would 
be normally distributed. 
Outcomes 
The main outcomes were the mean (SD) EQ-5D index and visual analogue scale (VAS) scores.  
Statistical analysis 
The EQ-5D descriptive system was scored according to the published instructions.35 EQ-5D index and 
VAS scores in patients with CDI were compared with published norms for the UK general population 
using Welch’s t-test.36 The EQ-5D population norm for patients aged 65-74 years was used for 
comparison, since the median age of patients in our study (70-years) was within this range.  
Results 
Part 1: Matched retrospective cohort study  
Demographics and CDI characterisation 
Sixty-four rCDI patients and 64 matched fCDI controls were included (range 8-14 pairs/centre). The 
pre-planned sample size of 75 matched pairs was not achieved owing to challenges with matching 
patients (as described in Figure 1). Patients’ demographic and clinical characteristics are summarised 
in Table 1.  
Thirty-three percent (21/64) of rCDI patients had severe CDI at the recurrent episode; 52% (33/64) 
had severe infection at their first episode, compared with 41% (26/64) of the matched fCDI controls. 
There was considerable heterogeneity in C. difficile strains identified, with 27 different ribotypes 
identified overall. Nine percent (6/64) of rCDIs, 11% (7/64) of the first episodes (in rCDI cases) and 8% 
(5/64) of fCDIs were attributable to the hypervirulent ribotypes 078 and 027, with other strains (most 
commonly 002, 014, 015) accounting for the majority of CDI cases. Thirteen rCDI patients (20%) had a 
different CDI strain compared with the isolate recovered from their first CDI episode (i.e. re-infection). 
Six percent (4/64) of rCDI cases (all with mild/moderate CDI) and 14% (9/64) of matched fCDI controls 
(5 severe, 4 mild/moderate CDI) died within the 28-day post-index period. The median duration of the 
post-index period in deceased patients was 13-days (IQR=7.3-18.8) for rCDI and 12-days (IQR=9.0-
16.0) for fCDI.  
Resource utilisation and costs 
The total costs of treating rCDI and fCDI patients during the 28-day post-index period are shown in 
Table 2. The median cost per patient was £7,539 (IQR=£5,617-£9,730) for rCDI and £6,294 
(IQR=£2,700-£9,216) for fCDI (cost difference, p=0.075). There were some outliers in the fCDI group, 
with three patients having total costs >£20,000.  
Because more fCDI than rCDI patients (9 versus 4, respectively) died during the post-index period, a 
post-hoc sensitivity analysis was conducted on data from the subgroup of 52 matched pairs where 
both patients survived to the end of the observation period (i.e. excluding both patients from pairs in 
which one died). In this group, median costs were similar to those for the overall sample: £7,888 
(IQR=£6,047-£9,866) and £6,719 (IQR=£3,329-£9,216) for rCDI and fCDI, respectively (Table 2).  
The differences in costs between matched rCDI and fCDI patients (cost for rCDI case minus cost for 
fCDI control) ranged from -£38,163 (fCDI>rCDI) to £11,841 (rCDI>fCDI), with a median difference of 
£689 (IQR=-£1,873-£3,954) (rCDI>fCDI) (Figure 2).  
Table 3 shows the breakdown of total costs. The cost of hospital admissions and ED visits accounted 
for the majority (>85%) of costs for both groups. The median cost for CDI-specific medicines was higher 
in rCDI patients (£376 per patient [IQR=£31-£1,521]) compared with fCDI (£46 [IQR=£2-£286]) (Table 
3). 
When stratified by severity, the median cost of CDI treatment per patient with severe infection was 
£5,631 (IQR=£2,910-£9,453) for fCDIs and £8,542 (IQR=£7,463-£10,532) for rCDIs (cost difference, 
p=0.039). When deceased patients were excluded, median costs were £6,961 (IQR=£4,464-£10,138) 
and £9,030 (IQR=£7,463-£10,288) for severe fCDIs and rCDIs, respectively (Table 2).  
The cumulative total number of bed days (median) in rCDI patients during the post-index period was 
1,171 (21) days compared with 1,027 (15.5) days for fCDI (difference, p=0.269). The highest median 
number of bed days (25.5) was observed in patients with a severe rCDI.  
The median cost for the between-episode period (rCDI only) was £2,973 (IQR=£778-£4,610) (Table 2). 
Part 2: Prospective patient self-assessment of QOL 
Demographics 
Thirty patients completed the EQ-5D-3L questionnaire during a CDI hospitalisation, of whom 63% 
(19/30) were male. The median age was 70.2 years (IQR=52-77). CDI was severe in 27% of patients 
(8/30) and mild/moderate in 73% (22/30).  
EQ-5D scores 
EQ-5D index and VAS scores for patients hospitalised with CDI compared with age-matched population 
norms are shown in Figure 3. The mean EQ-5D index score in CDI patients (0.42 [SD±0.29]) was 46% 
lower than the value for patients of similar age (65-74 years) in the UK general population (0.78) 
(difference, p<0.001); similar reduced scores were observed for the VAS (mean 47.82 [SD±21.93] for 
CDI, 38% lower than the general population score of 77.3, p<0.001). EQ-5D dimension scores are 
shown in Table 4.   
Discussion  
This non-interventional study used a matched retrospective cohort design to estimate the current 
costs associated with treatment of rCDI in hospitalised patients in the UK. It provides 
contemporaneous cost-burden data to aid decision-making by payers and clinicians on the targeting 
of resources for CDI treatment. The study also demonstrates the adverse impact of CDI on HrQoL, 
which has to-date been a largely neglected area of research. Taken together, the findings highlight the 
considerable burden that CDI places on patients and healthcare resources and the substantial financial 
costs associated with both fCDI and rCDI.  
In this study, there was considerable heterogeneity of strains causing CDI with 27 different strains 
identified overall. This pattern is consistent with the epidemiology of CDI in the UK, where no 
particular ribotypes are dominant and suggests an endemic (non-outbreak) population.12 It is 
therefore more representative to the wider UK patient population than data derived during a CDI 
epidemic. 
We found the total cost of treating CDI and hospital LOS to be higher for patients with rCDI compared 
with fCDI, although these differences were not statistically significant. This may be due to lack of 
power as a consequence of not meeting the planned sample size, but may also reflect the wide 
variation in costs between individual patients; this is typical in analyses of healthcare costs and has 
been observed in previous studies.1,37  It is also acknowledged that the differences between rCDI and 
fCDI costs may in part be due to the higher number of deaths in the fCDI group. When deceased 
patients were excluded, the difference between the groups was smaller than for the whole study 
sample but the cost remained higher for rCDI than fCDI. Recent systematic reviews have demonstrated 
incremental costs of $2,871-$4,846/case for primary CDI in US-based2 studies and £4,577-£8,843 in 
European studies.1 Although the median total cost for fCDI in the present study (£6,294) is consistent 
with these previous estimates, direct comparison is problematic due to methodological differences 
and variability in costs between different studies, partly due to differences in healthcare systems. Few 
studies have estimated the costs associated with rCDI specifically. One US study found that the cost 
of treating rCDI was $4,948 per-episode,31,38 which is broadly similar to the £7,539 observed in our 
study. However, our costs are lower than a recent single centre US study reported by Dubberke et al. 
(attributable costs $11,631 over 180-days)37 and those reported in a recent abstract (£20,249) 
presenting the results of a costing analysis in a single UK centre.39 This may reflect the use of different 
reference costs or the fact that we used a fixed 28-day observation period. The results of the present 
study provide an updated estimate of the UK costs associated with treating rCDI, which is important 
given the lack of contemporaneous data. Recently, new CDI medicines (fidaxomicin and 
bezlotoxumab) have been developed that have been shown to reduce CDI recurrence rates compared 
with conventional treatments.14,15 Our results will help clinical decision makers to evaluate the cost-
effectiveness of investing in these new medicines and the potential impact on local service provision. 
The resource utilisation between CDI episodes in rCDI patients (median £2,973) may represent 
previously un-recognised costs associated with treatment of patients with CDI once specific CDI 
treatment has ceased. 
Consistent with previous studies, the costs of treating CDI in this study were driven largely by the costs 
associated with the duration of hospital admissions, which accounted for >85% of total costs in both 
groups.40,1 However, the costs of CDI medicines were considerably higher in rCDI patients, reflecting 
the use of fidaxomicin in recurrent but not fCDI. The median LOS in rCDI cases was 21 days, which is 
similar to the 20.5 days reported previously in the UK.40 This similarity is perhaps surprising given that 
the previous UK study was reported in 1996, and significant efforts have been made to shorten 
hospital admissions in the intervening period.41 
The results presented here on the cost of treating CDI according to disease severity are important as 
PHE recommends different treatment strategies for patients with severe and mild/moderate 
disease.42 The highest median total cost was observed in severe rCDI cases (£8,542) and the lowest in 
patients with severe fCDI (£5,631), although as before, this may be explained partly by the higher 
number of deaths among fCDI patients with severe disease.  
HRQoL in hospitalised CDI patients is dramatically reduced compared with people of similar age in the 
general population, although from our descriptive study it is unclear whether this is directly 
attributable to CDI or more generally to the effects of the hospitalisation and associated co-
morbidities. Published EQ-5D norms for the general hospital population are not available and 
comparison with previous studies of hospitalised patients is problematic since most were conducted 
in patients with specific health conditions or those undergoing surgery, often in single centres or 
countries outside the UK. In one recent single centre study of patients (of similar age and gender 
distribution) on adult medical wards in a single UK hospital, the mean EQ VAS at the time of admission 
was 55.9, 14% higher than the CDI patients in our cohort.43 This would seem to suggest that the 
reduced HRQoL is at least partly attributable to CDI, but warrants further research. In our study the 
usual activities, mobility and self-care EQ-5D dimensions were most affected, which is unsurprising for 
a group of hospitalised patients. However, the anxiety and depression and pain dimensions were also 
impaired (63% reported moderate-extreme anxiety/depression; 67% reported moderate-extreme 
pain). Recent research has demonstrated that anxiety is common in patients hospitalised with CDI, 
with a number of CDI-specific concerns identified, including worry about future complications, 
physical concerns about ongoing symptoms and social concerns including interference with daily 
activities and finances.16 A limitation of the HRQoL data is that we did not collect information about 
co-morbidities or whether the patients had a first or recurrent CDI episode; further research is needed 
to fully understand the impact of each on HRQoL, as well as changes in HRQoL over time. 
Strengths and limitations 
The primary strength of this study is the matched design for estimation of costs, and the inclusion of 
descriptive QoL data; the latter is important to enable healthcare providers to determine the overall 
burden of CDI and has not been widely studied. The study was designed to minimise the impact of 
bias and confounding factors, however, there are limitations. The quality of the retrospectively-
sourced data relies upon the accuracy and completeness of patients’ medical records and there were 
instances (including medication details) where data were missing or incomplete. This is an inherent 
limitation of retrospective observational research, however, the impact of missing data in this study 
should be low because the primary endpoint is driven primarily by LOS, which was well-recorded. 
Furthermore, cases and controls would be affected equally. Despite age-matching, there were more 
deaths among fCDI patients, particularly in those with severe CDI; this suggests that either the rCDI 
patients in this study are a population of patients with less severe disease or that for the healthcare-
facility-acquired fCDI cases, the primary reason for hospitalization (not CDI) may be the main 
determinant of mortality. Although there were some differences in patient characteristics (particularly 
co-morbidities) between the two cohorts, we did not adjust for these factors in the analysis as they 
were not considered to be of sufficient magnitude to have introduced major bias into the results. 
Furthermore, it is not uncommon in CDI cohorts to observe modest imbalances in co-morbidities. We 
also used clear eligibility criteria and matched patients on the key characteristics related to the 
disease. The total costs associated with treating CDI may be underestimated because the post-index 
period was fixed at 28-days; also, the observation period started when CDI was confirmed and patients 
may have received CDI treatment before this. Only patients with a CDI that was confirmed by testing 
were included and consequently, the patient population may not be representative of all CDI cases. 
Testing practices and treatment protocols may have varied between the participating hospitals. These 
differences were not explored in the analysis owing to the small number of patients per centre and 
expected variability between individual patients. Despite all available eligible patients being included, 
the planned sample size of 75 matched pairs was not met due to challenges of matching patients. This 
may have affected the reliability of the cost estimates and limited the study’s ability to identify true 
differences between the groups. Furthermore, the formal sample size calculation applied only to the 
overall sample, not to subgroups. 
Conclusions 
This multicentre study demonstrates that CDI has a considerable impact on both patients and 
healthcare resources. The data provide an updated estimate of the “real-world” costs associated with 
rCDI management in the UK. These costs are largely driven by the duration of hospital admissions and 
are comparable to fCDI costs. The study also indicates increased costs associated with the treatment 
of patients with severe rCDI; this is important in light of PHE guidance, which recommends different 
treatment strategies for patients with severe and mild/moderate disease. Overall, the study provides 
contemporaneous data on the burden of CDI to patients and the healthcare system, which can be 
used to help clinical decision makers evaluate the cost-effectiveness of new CDI therapeutics, 
particularly those associated with reduced risk of recurrence.  
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Figure 1: Summary of matched retrospective cohort design and flow of patients through the study 
 
 
 
 
 
 
 
 
Table 1: Demographic characteristics of patients with rCDI and fCDI 
 Patients with recurrent Patients with first 
Characteristic CDI episode only CDI 
N 64 64 
Gender (n, %)   
Male 28 (44%) 28 (44%) 
Female 36 (56%) 36 (56%) 
Age (years)   
Median 77.0 76.5 
Interquartile range 68.5-84.1 66.9-84.1 
Co-morbidities (n, %)   
Cardiac disease 18 (28%) 17 (27%) 
COPD 19 (30%) 9 (14%) 
Hypertension 24 (38%) 19 (30%) 
Inflammatory bowel disease 3 (5%) 3 (5%) 
Renal disease 5 (8%) 10 (16%) 
Alzheimer’s/Dementia 9 (14%) 3 (5%) 
Atrial fibrillation 6 (9%) 6 (9%) 
Osteoarthritis 7 (11%) 6 (9%) 
Diabetes 14 (22%) 6 (9%) 
Diverticular disease 8 (13%) 9 (14%) 
Hypercholesterolemia 1 (2%) 4 (6%) 
Hypothyroidism 3 (5%) 2 (3%) 
Hyperparathyroidism 1 (2%) 1 (2%) 
Cancer 7 (11%) 15 (23%) 
Other 56 (88%) 52 (81%) 
 First episode Recurrent episode First episode 
Setting where CDI acquired    
Community 12 (19%) 4 (6%) 12 (19%) 
Healthcare facility 52 (81%) 60 (94%) 52 (81%) 
Severity of CDI*    
Mild/moderate 31 (48%) 42 (67%) 38 (59%) 
Severe 33 (52%) 21 (33%) 26 (41%) 
Strain of CDI    
Hypervirulent ribotypes     
078 6 (9%) 5 (8%) 4 (6%) 
027 1 (2%) 1 (2%) 1 (2%) 
Other strains (not 
hypervirulent) 
42 (66%) 43 (67%) 44 (69%) 
Unassigned/unable to grow 14 (22%) 15 (23%) 10 (16%) 
Not done or result unavailable 1 (2%) 0 (0%) 5 (8%) 
Abbreviations: CDI, Clostridium difficile infection; COPD, chronic obstructive pulmonary disease 
* Unavailable for 1 patient at recurrence; first episode was severe and therefore classified as severe 
for subsequent analyses 
 
  
Figure 2: Difference in total costs between individual rCDI cases and matched fCDI controls 
 
 
 
 
 
 
 Table 2: Resource utilisation and costs, overall and by CDI severity 
 
Patients with recurrent CDI Patients with first episode only CDI 
Mild/Moderate Severe Overall Mild/Moderate  Severe Overall 
Total costs (post-index period)* 
 n=42 n=22 n=64 n=38 n=26 n=64 
All patients £6,675 £8,542 £7,539 £6,518 £5,631 £6,294 
 (£4,419-£8,960) (£7,463-£10,352) (£5,617-£9,730) (£2,652-£9,086) (£2,910-£9,453) (£2,700-£9,216) 
Excluding patients who died  n=35 n=17 n=52 n=33 n=19 n=52 
(both patients in matched £6,907 £9,030 £7,888 £6,590 £6,961 £6,719 
pair excluded if one died) (£5,088-£9,290) (£7,463-£10,288) (£6,047-£9,866) (£2,392-£8,906) (£4,464-£10,138) (£3,329-£9,216) 
Total costs (between-episode period)* 
 n=40≠ n=22 n=62≠  
All patients £2,683 £3,280 £2,973 Not applicable 
 (£737-£5,351) (£1,028-£4,159) (£778-£4,610)  
Hospital bed days (post-index observation period)* 
 n=42 n=22 n=64 n=38 n=26 n=64 
All patients 15.5 25.5 21.0 20.0 14.5 15.5 
 (10-27) (21-27) (12-27) (7-27) (8-27) (7-27) 
Excluding patients who died  n=35 n=17 n=52 n=33 n=19 n=52 
(both patients in matched 18.0 26.0 21.0 21.0 18.0 19.5 
pair excluded if one died) (12-27) (22-27) (13-27) (6-27) (11-27) (7-27) 
* Reported as median (IQR) per patient 
≠ Two patients excluded (insufficient information to determine inter-episode period) 
 
Table 3: Breakdown of costs associated with treatment of rCDI and fCDI (post-index observation 
period) 
 Patients with recurrent CDI 
(n=64)* 
Patients with first episode only CDI 
(n=64)* 
Breakdown of costs 
% of total 
costs 
Median IQR 
% of total 
costs 
Median IQR 
Hospital bed days 86.7% £6,033 £4,002 - £7,767 88.6% £4,521 £2,240 - £7,767 
CDI-specific medicine≠ 5.4% £376 £31 - £1,521 0.9% £46 £2 - £286 
Other medicine 2.4% £170 £57 - £350 2.3% £119 £58 - £299 
Lab costsϮ 4.6% £319 £190 - £462 5.9% £304 £142 - £404 
ProceduresϮ  0.8% £54 £0 - £204 2.2% £111 £0 - £277 
IV /nutritional support 0.1% £6 £0 - £24 0.1% £4 £0 - £28 
Outpatient visits 0% £0 £0-£0 0% £0 £0 - £0 
Abbreviations: CDI, Clostridium difficile infection; IV, intravenous; IQR, interquartile range  
* Unless otherwise specified 
≠ 23 patients with rCDI were treated with fidaxomicin (median treatment duration 11 days); no 
patients with fCDI were treated with fidaxomicin 
Ϯ n=54 (one hospital excluded from analysis due to missing data) 
 
 
 
 
 
  
 
 
Figure 3: EQ-5D of patients hospitalised with CDI compared with UK general population norms for 
people aged 65-74 
 
 
* EQ-5D index: maximum score 1 (indicating full health). Lower scores indicate poorer HRQoL; EQ VAS: score range 0-100 
(0=Worst imaginable health state, 100=Best imaginable health state) 
UK population norms (age 65-74) as published36 
 
Table 4: EQ-5D Dimension scores 
EQ-5D Dimension 
Patients with CDI 
n=30  
n % 
Mobility 
No problems (1) 11 37% 
Some problems (2) 11 37% 
Confined to bed (3) 8 27% 
Self-care 
No problems (1) 14 47% 
Some problems (2) 9 30% 
Unable (3) 7 23% 
Usual activities 
No problems (1) 6 20% 
Some problems (2) 7 23% 
Unable (3) 17 57% 
Pain/discomfort 
No (1) 10 33% 
Some (2) 16 53% 
Extreme (3) 4 13% 
Anxiety/depression 
No (1) 11 37% 
Some (2) 15 50% 
Extreme (3) 4 13% 
 
